VX-950 and Peginterferon for Hepatitis C

Vertex Pharmaceuticals Incorporated20 enrolled

Overview

VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * infected with Hepatitis C virus Exclusion Criteria: * contraindications to peginterferon therapy

Call for information

Homburg/Saar, Germany

Call for information

Amsterdam, Netherlands

Viral kinetics

Assess the safety of VX-950 in combination with peginterferon

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.